TSE:TRIL

Trillium Therapeutics Stock Forecast, Price & News

C$11.81

+0.08 (+0.68 %)

(As of 06/11/2021 12:00 AM ET)

Add

Compare

Today's Range

C$11.57

▼

C$12.07

50-Day Range

C$9.05

▼

C$14.05

52-Week Range

C$7.74

▼

C$27.12

Volume104,439 shs

Average Volume187,229 shs

Market CapitalizationC$1.22 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive TRIL News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Trillium Therapeutics

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.

BRIEF-Trillium Therapeutics Says TTI-622 Monotherapy Shows 33% Response Rate
April 28, 2021 | msn.com

Value Investors: 1 Pharma Stock With Huge Potential and a Margin of Safety
April 26, 2021 | fool.ca

Trillium Therapeutics to Host Virtual R&D Day for Investors on April 28, 2021
April 22, 2021 | finance.yahoo.com

Is TRIL Stock A Buy or Sell?
April 8, 2021 | finance.yahoo.com

How Many Trillium Therapeutics Inc. (TSE:TRIL) Shares Do Institutions Own?
April 6, 2021 | finance.yahoo.com

3 Top Biotech Stocks for Spring 2021
March 25, 2021 | finance.yahoo.com

Trillium Therapeutics reports FY results
March 20, 2021 | seekingalpha.com

Canadian Markets Firmly Down In Negative Territory Despite Paring Some Losses
March 4, 2021 | nasdaq.com

TSX Ends On Firm Note Despite Weak Retail Sales Data
February 19, 2021 | markets.businessinsider.com

CANADA STOCKS-TSX falls as energy, materials drag
January 21, 2021 | nasdaq.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange TSE
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolTSE:TRIL
Previous SymbolTSE:SSS
CUSIPN/A
CIKN/A
Webwww.trilliumtherapeutics.com
Phone+1-416-5950627
Employees33
Year FoundedN/A

Sales & Book Value

Annual SalesC$148,000.00
Price / Sales8,230.05
Cash FlowC$2.67 per share
Price / Cash Flow4.42
Book ValueC$2.50 per share
Price / Book4.73

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares103,137,000
Market CapC$1.22 billion
Next Earnings Date8/10/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

0.90 out of 5 stars

2.0 Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of C$25.00, Trillium Therapeutics has a forecasted upside of 111.7% from its current price of C$11.81.
Amount of Analyst Coverage
Trillium Therapeutics has received no research coverage in the past 90 days.

2.5 Community Rank

Outperform Votes
Trillium Therapeutics has received 113 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Trillium Therapeutics has received 117 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Trillium Therapeutics has received 50.87% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote “Outperform” if you believe TRIL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRIL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Trillium Therapeutics does not currently pay a dividend.
Dividend Growth
Trillium Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Trillium Therapeutics insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Trillium Therapeutics is -16.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Trillium Therapeutics is -16.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Trillium Therapeutics has a P/B Ratio of 4.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Trillium Therapeutics (TSE:TRIL) Frequently Asked Questions

What stocks does MarketBeat like better than Trillium Therapeutics?

Wall Street analysts have given Trillium Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trillium Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Trillium Therapeutics' next earnings date?

Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Trillium Therapeutics.

How has Trillium Therapeutics' stock price been impacted by COVID-19?

Trillium Therapeutics' stock was trading at C$7.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TRIL stock has increased by 68.0% and is now trading at C$11.81.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for TRIL?

0 brokers have issued 12 month price targets for Trillium Therapeutics' shares. Their forecasts range from C$25.00 to C$25.00. On average, they anticipate Trillium Therapeutics' stock price to reach C$25.00 in the next year. This suggests a possible upside of 111.7% from the stock's current price.
View analysts' price targets for Trillium Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Trillium Therapeutics' key executives?

Trillium Therapeutics' management team includes the following people:

Dr. Jan Skvarka, Pres, CEO & Director (Age 54, Pay $812.5k)
Mr. James T. Parsons C.A., C.P.A., MAcc, CPA-CA, Chief Financial Officer (Age 56, Pay $543.38k)
Dr. Robert Uger, Chief Scientific Officer (Age 50, Pay $595.73k)
Dr. Penka Petrova, Chief Devel. Officer (Age 53, Pay $553.53k)
Dr. Ingmar Bruns M.D., Ph.D., Chief Medical Officer (Age 46, Pay $230k)
Benjamin Looker, Gen. Counsel
Dr. Rosemary Harrison, Sr. VP of Corp. Devel. & Strategy (Age 38)
Dr. Michael G. Hill, Head of Calgary Site
Ms. Kathleen Large, Sr. VP - Clinical Operations (Age 61)

Who are some of Trillium Therapeutics' key competitors?

Some companies that are related to Trillium Therapeutics include Cronos Group (CRON), Genus (GNS), BTG (BTG), Abcam (ABC), MorphoSys (MOR), Concordia International (CXR), PureTech Health (PRTC), Oxford Biomedica (OXB), Biotest Aktiengesellschaft (BIO), Ergomed (ERGO), Brooklyn ImmunoTherapeutics (BTX), Inventiva (IVA), Silence Therapeutics (SLN), Pfenex (PFNX) and Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI).
View all of TRIL's competitors.

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Canada Goose (GOOS), Moderna (MRNA), Shopify (SHOP), Square (SQ), Teladoc Health (TDOC), Zoom Video Communications (ZM), Advanced Micro Devices (AMD) and Canadian Natural Resources (CNQ).

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRIL."

How do I buy shares of Trillium Therapeutics?

Shares of TRIL and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Trillium Therapeutics' stock price today?

One share of TRIL stock can currently be purchased for approximately C$11.81.

How much money does Trillium Therapeutics make?

Trillium Therapeutics has a market capitalization of C$1.22 billion and generates C$148,000.00 in revenue each year.

How many employees does Trillium Therapeutics have?

Trillium Therapeutics employs 33 workers across the globe.

What is Trillium Therapeutics' official website?

The official website for Trillium Therapeutics is www.trilliumtherapeutics.com.

Where are Trillium Therapeutics' headquarters?

Trillium Therapeutics is headquartered at 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.

This page was last updated on 6/12/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here